An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Trial Status: active
This is an open-label, phase 1/2 study evaluating the safety, tolerability,
pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to
the body), and antitumor activity of CGT4859 in adult participants with intrahepatic
cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic
alternations.
Inclusion Criteria
Histologically confirmed locally advanced, metastatic, and/or unresectable iCCA or other solid tumor with documented FGFR2/3 alteration in blood and/or tumor.
Previously treated with, not appropriate for, or declined standard-of-care first-line treatment.
Have measurable disease per RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits.
Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), including resolution of clinically significant laboratory abnormalities, before the first dose of study drug. Exceptions are alopecia, hypothyroidism, or type 1 diabetes mellitus controlled with medical intervention, and paronychia controlled with local intervention. Key
Exclusion Criteria
Received chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug.
Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug.
Clinically significant corneal or retinal disorders or current evidence of retinal detachment.
Received more than 2 prior FGFRi therapies
Active, symptomatic, or untreated brain metastases unless the participant is clinically stable and off corticosteroids for ≥2 months.
Additional locations may be listed on ClinicalTrials.gov for NCT06777316.
